Ligand Q2 Revenue Jumps 34% on 32% Royalty Growth; Raises Low End of 2026 EPS Guidance
LGND has more than doubled off its 52-week low of $132.206.
Summary
Ligand reported Q2 2026 revenue of $63.7 million, up 34% year-over-year, driven by 32% royalty growth. The company raised the low end of its 2026 adjusted EPS guidance to $9.00 and highlighted the transformative XOMA acquisition, which closed in July and doubles its royalty portfolio.
Key Events · Earnings and Guidance · LGND
-
Q2 Revenue Up 34% on Royalty Strength
Total revenues reached $63.7 million, with royalty revenue of $48.0 million (up 32% YoY) driven by Filspari, Zelsuvmi, and Ohtuvayre. Adjusted diluted EPS was $2.37, up 48% YoY.
-
2026 Adjusted EPS Guidance Raised
Ligand raised the low end of its full-year adjusted EPS guidance to $9.00 (from $8.50), while reaffirming total revenue guidance of $270–$310 million. The increase reflects XOMA cost synergies and higher net interest income.
-
XOMA Acquisition Closed, Doubles Portfolio
The $739 million acquisition of XOMA Royalty closed on July 14, 2026, adding over 120 assets and more than doubling Ligand's royalty portfolio to over 200 programs. The deal is expected to add $0.50 and $1.50 to 2026 and 2027 adjusted EPS.
-
Key Partner Milestones
Filspari received FDA approval for FSGS and posted 96% YoY sales growth to $141 million. Ohtuvayre sales reached $204 million. Capvaxive gained an expanded pediatric indication and $184 million in sales. Volixibat received Breakthrough Therapy Designation for PSC.
Analysis · LGND · Life Sciences
A standout second quarter saw royalty revenue climb 32% year-over-year to $48 million, fueled by Filspari, Zelsuvmi, and Ohtuvayre. Total revenue advanced 34% to $63.7 million, while adjusted diluted EPS surged 48% to $2.37. Reflecting cost synergies from the recently closed XOMA acquisition and higher net interest income, the company lifted the low end of its full-year adjusted EPS guidance to $9.00. The XOMA deal, completed in July, more than doubles Ligand's royalty portfolio to over 200 assets and is expected to contribute $0.50 and $1.50 to 2026 and 2027 adjusted EPS, respectively. With $700 million in deployable capital and a diversified royalty base, Ligand is positioned for continued growth, though the stock already reflects much of the positive news given its $6 billion market cap.
At the time of this filing, LGND was trading at $302.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1B. The 52-week trading range was $132.21 to $326.63. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.